Catalysts for Gan & Lee Pharmaceuticals Co Ltd
3 tracked
Apr 30, 2026
phase 1 initiation
Gan & Lee Pharmaceuticals Co Ltd — GLR-2037 (Phase I Trial Initiation)
GLR-2037
→
Apr 29, 2026
phase 3 initiation
Gan & Lee Pharmaceuticals Co Ltd — (insulin aspart + insulin aspart protamine) (Phase III Trial Initiation)
(insulin aspart + insulin aspart protamine)
→
Apr 27, 2026
phase 3 initiation
Gan & Lee Pharmaceuticals Co Ltd — bofanglutide (Phase III Trial Initiation)
bofanglutide
→